Immunothérapie de la maladie d'Alzheimer et hypothèse amyloïde : lorsque l'agrégation obscurcit l'interprétation

Fox et al. (mercredi,) ont étudié cette question.

www.synapsesocial.com/papers/69f41bb2ef2b80c36f936b19 — DOI: https://doi.org/10.1016/s0140-6736(26)00789-0

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease· 2022 · 209 citations
2. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease· 2014 · 1,958 citations
3. Expectations and clinical meaningfulness of randomized controlled trials· 2023 · 88 citations
4. Preparing for disease-modifying therapies in Alzheimer's disease· 2023 · 71 citations
5. The quality of life of patients with dementia and their caregivers: important and yet inadequately assessed· 2025 · 1 citations